Recent IPO activity and a visible pipeline of scheduled listings form the core driver of trader sentiment on whether any IPOs occur before 2027. Multiple U.S. offerings, including TRex Bio and Retension Pharmaceuticals priced for October 9, 2026, alongside earlier 2026 debuts such as SpaceX and Accelevation, demonstrate continued access to public markets despite selective demand and volatility in yields. AI-related names and infrastructure plays continue to attract institutional interest, with Anthropic reportedly targeting a potential November window following its confidential filing. Key upcoming catalysts include October and November pricing dates plus any regulatory approvals, though market conditions could still prompt delays for smaller or less compelling deals.